Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial.
Bjørn Staehr MadsenJonel TrebickaMaja ThieleMads IsraelsenManimozhiyan ArumuganTroels HavelundAleksander KragPublished in: Trials (2018)
EudraCT, 2014-001856-51 . Registered on 16 August 2014.
Keyphrases